GR-89696

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
GR-89696
GR-89696 structure.png
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H25Cl2N3O3
Molar mass414.325 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

GR-89696 is a drug which acts as a highly selective κ-opioid agonist.[1] It shows selective effects in different animal models and it is thought it may be a subtype-selective agonist for the κ2 subtype.[2][3][4] Recent studies have suggested that GR-89696 and related κ2-selective agonists may be useful for preventing the itching which is a common side effect of conventional opioid analgesic drugs, without the additional side effects of non-selective kappa agonists.[5]

References[edit]

  1. ^ Naylor A, Judd DB, Lloyd JE, Scopes DI, Hayes AG, Birch PJ (July 1993). "A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines". Journal of Medicinal Chemistry. 36 (15): 2075–83. doi:10.1021/jm00067a004. PMID 8393489.
  2. ^ Herrero JF, Headley PM (September 1993). "Functional evidence for multiple receptor activation by kappa-ligands in the inhibition of spinal nociceptive reflexes in the rat". British Journal of Pharmacology. 110 (1): 303–9. doi:10.1111/j.1476-5381.1993.tb13809.x. PMC 2176008. PMID 8220893.
  3. ^ Ho J, Mannes AJ, Dubner R, Caudle RM (April 1997). "Putative kappa-2 opioid agonists are antihyperalgesic in a rat model of inflammation". The Journal of Pharmacology and Experimental Therapeutics. 281 (1): 136–41. PMID 9103490.
  4. ^ Butelman ER, Ko MC, Traynor JR, Vivian JA, Kreek MJ, Woods JH (September 2001). "GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys". The Journal of Pharmacology and Experimental Therapeutics. 298 (3): 1049–59. PMID 11504802.
  5. ^ Ko MC, Husbands SM (January 2009). "Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates". The Journal of Pharmacology and Experimental Therapeutics. 328 (1): 193–200. doi:10.1124/jpet.108.143925. PMC 2719014. PMID 18842704.